Advertisement

Pharmaceutical Medicine

, Volume 33, Issue 6, pp 519–530 | Cite as

The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval

  • Elisa Martín-MerinoEmail author
  • Ana Llorente-García
  • Belén Castillo Cano
  • Dolores Montero Corominas
  • Consuelo Huerta-Álvarez
Original Research Article
  • 16 Downloads

Abstract

Background

In Spain, girls are vaccinated against human papillomavirus (HPV) in the primary care setting, according to a national vaccination programme. Vaccination is voluntary and is covered by the public health system.

Objectives

The aim of the study was to estimate the incidence and patterns of HPV vaccination amongst girls in primary care in Spain.

Methods

A cohort study was performed using the information recorded in the Spanish Primary Care Database for Pharmacoepidemiological Research (BIFAP) from 7.9 million patients from seven Spanish regions, between 2001 and 2016 (56.6% of the regional population). Data available in BIFAP include patient age, sex, life-style factors, clinical events, specialist referrals, prescriptions, and vaccinations as recorded by the primary care physician (PCP) or administering nurse. The study cohort comprised all girls aged 9–18 years registered in BIFAP between 1st January of 2007 and 31st December of 2016 who had at least 1 year of clinical record information with their PCP (inclusion criteria). The date the inclusion criteria were met was designated as the start date to the study cohort contribution. In order to estimate the incidence of HPV vaccination (initiation of vaccination schedule), girls with an HPV vaccination recorded before the start date or without vaccination date were excluded. Girls forming the study cohort were followed from start date until there was a recorded HPV vaccination, they reached 19 years of age or died, end of available information, or 31st December 2016. The person-time of all patients forming the study cohort was reckoned in the incidence estimations. The follow-up was replicated yearly from 2007 to 2016. The cumulative incidence (CuIn) of vaccination by birth cohort, year and region, was estimated using life tables (proportion of vaccination by intervals in which the denominator is the initial population corrected for losses).

Results

Of 388,690 girls forming the study population, 154,211 initiated the vaccination during 2007–2016. Ages ranged from 12 to 14 years at first dose in 84.5% of vaccinated girls, 42.79% received a quadrivalent vaccine, 21.86% a bivalent vaccine, and 35.35% an unknown type. Of the vaccinated population, 48.0% were completely vaccinated with a three-dose schedule and 28.9% with a two-dose schedule, 20.2% received one dose and 3.0% two doses in a three-dose schedule, at a maximum of 10 years of follow-up. The CuIn was highest among girls aged either 13 or 14 years over all regions (reaching 92.8% and 89.7%, respectively), and aged 12 in some regions/years (up to 89.8%). Girls aged 15 years were also vaccinated (although showing lower yearly incidence, i.e. < 69.1%) in two regions. The coverage was broadened to younger girls (11 years) during the last years of the study period in some regions.

Conclusions

According to BIFAP primary care data, a high incidence of vaccination among girls aged 13–14 years was observed. Vaccination among younger and older girls were less common, although they reached high incidence in some regions and/or years. Most vaccination patterns adjusted to a complete vaccination regimen, as recommended posology.

Notes

Acknowledgements

The authors would like to acknowledge the excellent collaboration of the primary care general practitioners, paediatricians, and nurses taking part in the primary care records and the support of the regional governments, with special mention to physicians participating in a general survey about vaccination recording in primary care, which helped us to better understand specific information registered in the database. We are also grateful to Mónica Ríos Martinez from BIFAP team for her review of patients’ profiles as well as to Veronica Bryant and Julio Bonis for making the conducting of the survey possible. We also thank the retraction team of Pharmaceutical Medicine for allowing us to retract our previous publication [29] after realizing calculation errors by calendar year and submit the current manuscript with new data and updated calculations. All views expressed in this article are those of the authors and do not represent the views of, and should not be attributed to, the Spanish Agency for Medicines and Medical Devices.

Compliance with Ethical Standards

Funding

BIFAP is funded by the Spanish Agency for Medicines and Medical Devices. This study was performed within the framework of a project on the safety of HPV vaccine. This study has been funded by Instituto de Salud Carlos III through the project “PI17/02300” (Co-funded by European Regional Development Fund/European Social Fund “Investing in your future”).

Conflict of interest

Elisa Martín-Merino, Ana Llorente-García, Belén Castillo Cano, Dolores Montero Corominas and Consuelo Huerta-Álvarez have no conflict of interest to declare.

Ethical Approval

The investigators had access to secondary use of only fully anonymised data, and under this condition, no specific ethics review was required according to Spanish law.

References

  1. 1.
    Grupo de Trabajo VPH (2012) de la Ponencia de Programa y Registro de Vacunaciones. Revisión del Programa de Vacunación frente a Virus del Papiloma Humano en España Ponencia de Programa y Registro de Vacunaciones Grupo de trabajo VPH 2012 [Internet]. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad; 2013 [cited 10 Oct 2019]. Report No.: Informes, estudios e investigación 2013. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/PapilomaVPH.pdf
  2. 2.
    Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; 2011 [cited 31 May 2018]. https://www.aemps.gob.es/informa/boletines-AEMPS/boletinMensual/2011/octubre/docs/informe-mensual_octubre-2011.pdf.
  3. 3.
    European Medicines Agency. Assessment report. CHMP variation assessment report. Type II variation EMEA/H/C/000721/II/0021. Cervarix. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) Procedure No.: EMEA/H/C/000721/II/0021 [Internet]. 2011 Oct. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000721/WC500121597.pdf. Accessed 7 Nov 2019.
  4. 4.
  5. 5.
    Pérez-Martín J, Navarro-Alonso JA, Cayuela-Fuentes J, Bernal-González P. Vaccination program against HPV in women with excisional treatment due to preneoplasic cervical lesions in the region of Murcia: results of the first year. Clin Res Infect Dis. 2016;3(3):1031.Google Scholar
  6. 6.
    Coordinador: Campins MLA, Bayas JM, Borruel N, Castellsagué CM, Campins XC, Curran A, Díaz de Heredia C, Martínez X, Moraga-Llop FA, Torné A. AEPCC-Guía: Vacunación selectiva frente al virus del papiloma humano en poblaciones de riesgo elevado. Publicaciones AEPCC; 2016.Google Scholar
  7. 7.
    de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.CrossRefGoogle Scholar
  8. 8.
    Gardasil 9. Ficha técnica o resumen de las características del producto [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; 2015 [cited 31 May 2018]. https://cima.aemps.es/cima/pdfs/es/ft/1151007002/FT_1151007002.html.pdf
  9. 9.
    Castellsagué X, Iftner T, Roura E, Vidart JA, Kjaer SK, Bosch FX, et al. Prevalence and genotype distribution of human papillomavirus infection of the cervix in Spain: the CLEOPATRE study. J Med Virol. 2012;84(6):947–56.CrossRefGoogle Scholar
  10. 10.
    Xunta de Galicia. Prevalencia de VPH de alto risco nas mulleres galegas. Xunta de Galicia; 2012. (Boletín Epidemiolóxico de Galicia). Report No.: XXIV-no 2.Google Scholar
  11. 11.
    Alemany L, Pérez C, Tous S, Llombart-Bosch A, Lloveras B, Lerma E, et al. Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. Gynecol Oncol. 2012;124(3):512–7.CrossRefGoogle Scholar
  12. 12.
    83.000 niñas han recibido la vacuna del papiloma humano en la Región desde 2008. Murciasalud, el portal sanitario de la Región de Murcia. Consejería de Salud de Murcia [Internet]. 2018 [cited 11 Jan 2019]. http://www.murciasalud.es/noticias.php?op=ver&id=427580&idsec=66.
  13. 13.
    Orden Foral 97/2007, de 3 de agosto, de la Consejera de Salud, por la que se modifica el Calendario Oficial de Vacunaciones de Navarra. Boletín Oficial de Navarra; 2007.Google Scholar
  14. 14.
    Limia A, Pachón I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2011;16(21):19873.Google Scholar
  15. 15.
    Resolución de 24 de julio de 2013, de la Dirección General de Salud Pública, Calidad e Innovación, por la que se publica el Acuerdo del Consejo Interterritorial del Sistema Nacional de Salud sobre el calendario común de vacunación infantil. [Internet]. 2013. https://www.boe.es/diario_boe/txt.php?id=BOE-A-2013-8700. Accessed 7 Nov 2019.
  16. 16.
    Cervarix. Assessment Report. EMA/789820/2013. Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency [Internet]. 2013 Nov [cited 31 May 2018]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000721/WC500160885.pdf. Accessed 7 Nov 2019.
  17. 17.
    Gardasil-H-C-703-WS-472: EPAR—Assessment report—Variation. EMA/CHMP/66618/2014 [Internet]. European Medicines Agency; 2014. https://www.ema.europa.eu/en/documents/variation-report/gardasil-h-c-703-ws-472-epar-assessment-report-variation_en.pdf. Accessed 7 Nov 2019.
  18. 18.
    Evolución coberturas de sarampión, rubeola y parotiditis (TV) y virus del papiloma humano (VPH). ESPAÑA 2008-2017 (actualización). [Internet]. Ministerio de Sanidad, Consumo y Bienestar Social. http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla3.pdf. Accessed 7 Nov 2019.
  19. 19.
    Agencia Española del Medicamento y Productos Sanitarios. BIFAP: Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [Internet]. [cited 10 Oct 2019]. http://bifap.aemps.es/.
  20. 20.
    Salvador Rosa A, Moreno Pérez JC, Sonego D, García Rodríguez LA, de Abajo Iglesias FJ. The BIFAP project: database for pharmaco-epidemiological research in primary care. Atencion Primaria Soc Esp Med Fam Comunitaria. 2002;30(10):655–61.CrossRefGoogle Scholar
  21. 21.
    Martín Merino E, Huerta Álvarez A, Gil García M, Macia Martínez M.A. Álvarez Gutiérrez A. Experiencia de investigación Pública con BIFAP, una fuente de datos para farmacoepidemología. In Sevilla: Gac Sanit. 2016; 30 Supl Congr:I-III. p. 281.Google Scholar
  22. 22.
    Porcentaje de población cubierta por el sistema sanitario publico. Encuesta Nacional de Salud. MSSSI/INE. Indicadores clave del Sistema Nacional de Salud [Internet]. [cited 10 Oct 2019]. http://inclasns.msssi.es/main.html.
  23. 23.
    Instituto Nacional de Estadística. (Spanish Statistical Office) [Internet]. [cited 10 Oct 2019]. https://www.ine.es/.
  24. 24.
    Martin-Merino E, Llorente-Garcia A, Montero-Corominas D, Huerta C. The recording of human papillomavirus (HPV) vaccination in BIFAP primary care database: a validation study. Pharmacoepidemiol Drug Saf. 2019;28(2):201–8.CrossRefGoogle Scholar
  25. 25.
    Summary of the European public assessment report for Gardasil. European Medicines Agency [Internet]. European Medicines Agency. 2018 [cited 11 June 2019]. https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil.
  26. 26.
    European Medicines Agency. Summary of the European public assessment report for Cervarix [Internet]. European Medicines Agency. 2018 [cited 11 June 2019]. https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix.
  27. 27.
    Szklo M, Nieto FJ. Measuring disease occurrence. In: Epidemiology Beyond the Basics. 2014. pp. 47–77.Google Scholar
  28. 28.
    ltable—Life tables for survival data. STATA manuals [Internet]. [cited 10 Oct 2019]. http://www.stata.com/manuals13/stltable.pdf.
  29. 29.
    Martín-Merino E, Llorente-García A, Montero Corominas D, Huerta-Álvarez C. The longitudinal incidence of human papillomavirus vaccination in spanish primary care in the first 6 years after approval. Pharm Med. 2019;33(2):135–44.CrossRefGoogle Scholar
  30. 30.
    Martín-Merino E, Llorente-García A, Montero Corominas D, Huerta-Álvarez C. Retraction Note to: The longitudinal incidence of human papillomavirus vaccination in Spanish primary care in the first 6 years after approval. Pharm Med. 2019;33(4):367.CrossRefGoogle Scholar
  31. 31.
    Orden 369/2015, de 10 de abril, del Consejero de Sanidad, por la que se da publicidad al Acuerdo adoptado por el Consejo Interterritorial del Sistema Nacional de Salud, en su reunión de 14 de enero de 2015, sobre el Calendario de Vacunación Infantil del Sistema Nacional de Salud, y se actualiza el Calendario Vacunal Infantil de la Comunidad de Madrid. Consejería de Sanidad. [Internet]. Boletín Oficial de la Comunidad de Madrid; 2015 [cited 11 June 2019]. http://www.madrid.org/wleg_pub/secure/normativas/contenidoNormativa.jsf?opcion=VerHtml&nmnorma=8921&cdestado=P#no-back-button.
  32. 32.
    Orden SAN/51/2015, de 5 de febrero, por la que se actualiza el Calendario Oficial de Vacunaciones Sistemáticas de la Infancia de la Comunidad de Castilla y León [Internet]. Boletín Oficial de Castilla y León; 2015. http://bocyl.jcyl.es/html/2015/02/16/html/BOCYL-D-16022015-3.do. Accessed 7 Nov 2019.
  33. 33.
    Calendarios de vacunación en España 1975-2015. Ministerio de Sanidad, Consumo y Bienestar Social [Internet]. Histórico de Calendarios de Vacunación. 2019. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CalendariosVacunacion1975_2015.pdf. Accessed 7 Nov 2019.
  34. 34.
    Grupo de trabajo de la Ponencia de Programa y Registro de Vacunaciones. Virus del papiloma humano. Situación actual, vacunas y perspectivas de su utilización. [Internet]. Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Servicios Sociales e Igualdad.; 2007 [cited 10 Oct 2019]. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/VPH_2007.pdf.
  35. 35.
    Ministerio de Sanidad, Servicios Sociales e Igualdad. Coberturas de vacunación frente a virus del papiloma humano (VPH). Pauta completa niñas de 11-14 años. Comunidades autónomas 2015 o curso escolar 2014-2015 [Internet]. [cited 10 Oct 2019]. http://www.msps.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla8.pdf.
  36. 36.
    Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain. Vaccine. 2017;35(25):3342–6.CrossRefGoogle Scholar
  37. 37.
    Sheridan A, White J, Barlow T, Soldan K. Annual HPV vaccine uptake in England: 2008/09. Routine programme for year 8 girls (12–13 years old) and catch-up campaign for year 13 girls (17–18 years old) [Internet]. 2010 Jan [cited 11 Oct 2019]. http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_111676.pdf.
  38. 38.
    Ferriero A, Specchia M, Cadeddu C, Lovato E, Ricciardi W. State of art of anti-Human Papillomavirus vaccination programs and vaccine coverage levels: comparison between Italy and others European countries. Eur J Public Health. 2014;24:161.CrossRefGoogle Scholar
  39. 39.
    ANSM/CNAMTS. Vaccins anti-HPV et risque de maladies auto-immunes : étude pharmacoépidémiologique [Internet]. 2015 Sept [cited 11 Oct 2019]. https://ansm.sante.fr/content/download/80841/1023043/version/2/file/Ansm_Gardasil-Hpv_Rapport_Septembre-2015_Version-2.pdf.
  40. 40.
    Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, LoCasale R, et al. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21(1):1–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Pharmacoepidemiology and PharmacovigilanceSpanish Agency of Medicines and Medical Devices (AEMPS)MadridSpain

Personalised recommendations